{"prompt": "['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', 'DURATION OF STUDY PERIOD (per', 'Total duration of study (per patient) is expected to be up to 681 weeks:', 'patient)', '4 (+1) weeks for screening', '52 weeks of treatment', '12 weeks of post-treatment follow-up', 'Property of the Sanofi Group - strictly confidential', 'Page 19', 'VV-CLIN-0528583 6.0']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '1', 'FLOW CHARTS', '1.1', 'OVERVIEW OF STUDY DESIGN', '>30 kg Dupilumab 200 mg q2w SC', 'Or', '268 patients', '<30 kg Dupilumab 100 mg q2w SC', 'R*', 'Screening', '\u20ac', 'Randomized Treatment', '<', 'Post', '(4+1)Weeks', 'Up to 52 Weeks', 'Treatment', '12 Weeks', '<', 'Matching placebo 200 mg q2w SC', '134 patients', 'Or', 'Matching Placebo 100 mg q2w SC', 'Week -4+1', 'Week 0/D1', 'Week 52', 'Week 64', 'EOT', 'EOS', 'Background medication: medium dose ICS + second controller or high dose ICS alone or + second controller', 'D: day; EOT: end of treatment; EOS: end of study; ICS: inhaled corticosteroids; q2w: every 2 week; R: randomization; SC: subcutaneous', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583', 'Page 20']['Amended Clinical Trial Protocol 03', '18-Oct-2019', 'EFC14153 - dupilumab', 'Version number: 1', '1.2', 'STUDY FLOW CHART', 'Post-', 'SCR', 'Randomized Treatment Period', 'treatment', 'Period', 'RND', 'EOT\u00b0', 'EOS', 'Week', '-4 (+1)', '0', '2', '4', '6', '8', '10', '12', '14', '16', '18', '20', '22', '24', '26', '28', '30', '32', '34', '36', '38', '40', '42', '44', '46', '48', '50', '52', '56', '60', '64', 'Visite', '1', '2', '3', '4', '5', '6', '7', '8', '9', '10', '11', '12', '13', '14', '15', '16', '17', '18', '19', '20', '21', '22', '23', '24', '25', '26', '27', '28', '29', '30', '31', 'Informed Consent/Assent', 'Inclusion/Exclusion Criteria', 'Patient Demography', 'Medical/Surgical History9, and', 'Reversibilityh', 'Physical Examination', 'Menstruation status', 'Vital Signs/ (including height and weight)', 'Dispense or download electronic diary/', 'PEF meter', 'Health Care Resource Utilization (HCRU)', 'Randomization', 'Call IVRS/IWRS', 'Treatment', 'Investigational Product Administration', 'm', 'm', 'Dispense/review of diary for Home', '(optional) by parent/caregiver', 'Efficacy Assessments', 'Spirometry', 'X', 'Post-bronchodilator FEV1n', 'Patient Reported Outcomes / HRQoL', 'ACQ-IAP', 'PAQLQ(S)-IA (for patients >7 years old', 'at Randomization V2)P', 'PRQLQ-IA q', 'Property of the Sanofi Group - strictly confidential', 'VV-CLIN-0528583 6.0', 'Page 21']\n\n###\n\n", "completion": "END"}